Patients treated with trastuzumab deruxtecan ... in combination with pertuzumab as a first-line treatment for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic ...

The DESTINY-Breast09 trial showed that first-line fam-trastuzumab deruxtecan plus pertuzumab improved progression-free survival in HER2+ metastatic breast cancer. Fam-trastuzumab deruxtecan-nxki ...

compared with standard taxane plus trastuzumab and pertuzumab (THP) therapy in the frontline treatment of patients with HER2-positive metastatic breast cancer, according to interim results from the ...

In the Phase III DESTINY-Breast09 trial, Enhertu (trastuzumab deruxtecan) and Perjeta (pertuzumab) significantly improved progression-free survival compared to the current standard of care in the ...

trastuzumab and pertuzumab (THP) as a 1st-line treatment for patients with HER2-positive metastatic breast cancer. The PFS improvement was seen across all pre-specified patient subgroups with ...

When the mutation is present, the overproduction of HER2 proteins drives the growth of breast cancer cells. Therapies that specifically target HER2 include Herceptin (trastuzumab), Perjeta (pertuzumab ...

Results: HER2 internalization was enhanced in NSCLC cells expressing mutant forms of HER2 compared with those expressing HER2(WT). Homodimers of HER2(WT) were localized mainly at the cell surface, ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

Therapies that specifically target HER2 include Herceptin (trastuzumab), Perjeta (pertuzumab), and Kadcyla (trastuzumab ...